1,745
Views
0
CrossRef citations to date
0
Altmetric
Articles

Prostate cancer specific mortality after 5α-reductase inhibitors medication in benign prostatic hyperplasia patients: systematic review and meta-analysis

, , , , &
Pages 80-91 | Received 12 May 2021, Accepted 23 Jun 2021, Published online: 10 Dec 2021

References

  • Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807–1823.
  • Kohaar I, Petrovics G, Srivastava S. A rich array of prostate cancer molecular biomarkers: opportunities and challenges. IJMS. 2019;20(8):1813.
  • Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–224.
  • McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338(9):557–563.
  • Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–441.
  • Zhu J, Gao J, Xu A, et al. The influence of benign prostatic hyperplasia drugs on incidence and pathology grading of prostate cancer. Zhonghua wai ke za zhi. Chinese Journal of Surgery]. 2010;48(10):761–763.
  • Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–1202.
  • Preston MA, Wilson KM, Markt SC, et al. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014;174(8):1301–1307.
  • Luo L-M, Yang R-D, Wang J-M, et al. Association between 5α-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis. Asian J Androl. 2020;22(5):532.
  • Wallner LP, DiBello JR, Li BH, et al. 5-alpha reductase inhibitors and the risk of prostate cancer mortality in men treated for benign prostatic hyperplasia. Paper Presented at: Mayo Clinic Proceedings. 2016;91(12):1717–1726.
  • Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341.
  • Shim SR, Kim S-J. Intervention meta-analysis: application and practice using R software. Epidemiol Health. 2019;41:e2019008.
  • Shim S-R, Shin I-S, Bae J-M. Intervention meta-analysis using STATA software. J Health Info Stat. 2016;41(1):123–134.
  • Ishizuka O, Nishizawa O, Hirao Y, et al. Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy . Int J Urol. 2002;9(11):607–612.
  • Niu Y, Ge R, Hu L, et al. Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate. 2011;71(12):1317–1324.
  • Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1999;41(4):550–554.
  • Clark RV, Hermann DJ, Gabriel H, et al. Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel, dual 5 alpha reductase inhibitor. The Journal of Urology. 1999;53(1):161–168.
  • Pritchard CC, Nelson PS. Gene expression profiling in the developing prostate. Differentiation. 2008;76(6):624–640.
  • Huggins C. Endocrine-induced regression of cancers. Science. 1967;156(3778):1050–1054.
  • Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. The Journal of Urology. 2002;167(2 Part 1):528–534.
  • D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama. 1998;280(11):969–974.
  • Schatzl G, Madersbacher S, Haitel A, et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol. 2003;169(4):1312–1315.
  • Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res. 1999;59(17):4161–4164.
  • Karakiewicz PI, Bazinet M, Aprikian AG, et al. Outcome of sextant biopsy according to gland volume. Urology. 1997;49(1):55–59.
  • Basillote JB, Armenakas NA, Hochberg DA, et al. Influence of prostate volume in the detection of prostate cancer. Urology. 2003;61(1):167–171.
  • Sarkar RR, Parsons JK, Bryant AK, et al. Association of treatment with 5α-reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern Med. 2019;179(6):812–819.